Cell and Gene Therapy

The Future of Cell and Gene Therapy QC

Cell and Gene Therapy (CGT) is revolutionizing the treatment of diseases once thought untreatable. For cell-based therapies, maintaining and assessing genomic integrity throughout culture, reprogramming, editing, and differentiation remains a considerable challenge.

Effective therapies depend on the thorough detection of variants, which presently requires a combination of advanced tools, such as next-generation sequencing (NGS), microarrays, fluorescence in situ hybridization (FISH), and karyotyping. While these methods can detect various chromosomal changes and CNVs, emerging evidence suggests that many structural variants (SVs) may go undetected using traditional approaches. These missed SVs can play a critical role in genomic stability and therefore therapeutic safety. In addition, the widespread adoption of genome engineering technologies like CRISPR has introduced new quality control challenges. Beyond intended edits, these tools can create unintended structural alterations at both on-target and off-target sites that may compromise therapeutic safety and efficacy.

These evolving challenges require researchers to:

• Ensure genome stability by thoroughly evaluating structural variants for safer, more effective therapeutic outcomes.
• Accurately detect genome engineering outcomes, capturing both intended modifications and unintended structural changes that fall below the detection threshold of traditional technologies.

The OhmX Platform addresses these critical needs by providing comprehensive structural variant detection from 300 bp to Mb size chromosome changes in a single assay. Unlike traditional methods that require multiple technologies and may still miss key variants, EGM offers unbiased, genome-wide SV detection with the resolution and sensitivity needed for rigorous CGT quality control.

Building on EGM’s comprehensive SV detection capabilities, experience the advantages that set the OhmX Platform apart from traditional tools:

• Redefining Genome Integrity Analysis
  Unlock unparalleled clarity in genomic characterization with precision that spans structural variants and chromosomal aberrations from 300 bp to several megabases. This transformative capability delivers a complete view of the genome, laying a foundation of certainty for your cell and gene therapy (CGT) breakthroughs. Build every step of your process on the most comprehensive genomic insights available.
• Empowering Genome Engineering Excellence
  Transform detection into actionable discovery. The OhmX Platform reveals the unseen—subtle regions influencing CRISPR edits, including off-target effects, incomplete modifications, and unexpected rearrangements. With these insights, you can refine your strategies and accelerate therapeutic advancements, pushing boundaries with confidence and precision.
• End-to-End Support & Accessibility
  From start to finish, we’re with you. The OhmX Platform pairs cutting-edge technology with expert bioinformatics and customer support, ensuring you maximize the impact of every analysis. Through our accessible Reagent Rental Program, we remove barriers by eliminating upfront capital investment, enabling teams of all sizes to harness the power of OhmX. Together, let’s drive innovation forward.
• Simplified Cost Structure
  Experience full-spectrum genome integrity analysis at a fraction of the cost of traditional long-read sequencing methods. The streamlined OhmX model simplifies budgeting, accelerates decision-making, and clears the path for confident scaling. Redefine what's possible with an approach that frees resources for exploration and discovery.

The OhmX Platform powers breakthroughs across today’s most pressing challenges and tomorrow’s scientific frontiers. By delivering unmatched resolution for structural variant detection, OhmX reveals genomic details ranging from 300 base pairs to several megabases—insights that sequencing-based methods routinely miss. This groundbreaking resolution provides a deeper understanding of genome architecture and stability, unlocking clarity into regions critical for cell and gene therapy development, genome editing workflows, and translational research.

With its ability to perform comprehensive whole-genome integrity evaluations, OhmX enables researchers to identify chromosomal aberrations, rearrangements, and hidden instabilities across the entire genome. This complete view of genomic stability provides the confidence needed to design, refine, and advance therapeutic strategies with precision.

Built with scalability in mind, the platform adapts seamlessly from exploratory discovery projects to regulated clinical development. Its modular workflows, streamlined sample preparation, and efficient throughput make it equally suited for small research groups and large translational programs, ensuring consistency and reliability at every stage.

Looking ahead, the OhmX Platform is designed not only for today’s challenges, but also for tomorrow’s opportunities. Its flexible architecture and evolving bioinformatics pipelines allow researchers to stay ahead of innovation, transforming complex genomic questions into actionable insights that drive the future of genome engineering.